

Bevacizumab E2100

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Only improved PFS mature data shows no OS advantage and no improved QoL



Bevacizumab E2100

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: First-line treatment of adult patients with metastatic breast cancer

Experimental Arm: Bevacizumab + Paclitaxel

Control Arm: Paclitaxel



